Lower mortality, improved remission and event-free survival rates, lower relapse rates
MONDAY, April 23 (HealthDay News) -- Adolescent and young adult patients with acute lymphoblastic leukemia (ALL) who are treated with pediatric-inspired regimens exhibit lower all-cause mortality, higher complete remission and event-free survival rates, and lower relapse rates compared with those treated with conventional adult-chemotherapy regimens, according to a study published in the May issue of the American Journal of Hematology.
Ron Ram, M.D., of Tel-Aviv University in Israel, and colleagues conducted a systematic review and meta-analysis of 11 published comparative studies reporting results from 2,489 adolescent and young adult patients, aged 16 to 39 years, with ALL. The safety and efficacy of pediatric-inspired induction chemotherapy regimens were compared with conventional-adult chemotherapy.
The researchers found that all-cause mortality at three years was significantly lower for adolescent and young adult patients treated with pediatric-inspired chemotherapy compared with conventional-adult chemotherapy regimens (relative risk [RR], 0.58). Those treated with pediatric-inspired regimens had superior complete remission rates after induction chemotherapy (RR, 1.05; 95 percent confidence interval, 1.01 to 1.10) and improved event-free survival (RR, 1.66). Although nonrelapse mortality was similar between the two groups, the relapse rate was significantly lower in pediatric-inspired regimen-treated adolescents and young adults (RR, 0.51).
"Pediatric-inspired regimens are superior to conventional-adult chemotherapy in adolescent and young adult ALL patients," the authors write. "Further randomized controlled studies to investigate this approach in adult ALL patients are warranted.
Full Text (subscription or payment may be required)